Showing posts with label RSI. Show all posts
Showing posts with label RSI. Show all posts
Sunday, April 25, 2010
Ketamine and Etomidate: Good Choices for RSI in Critically Ill Patients:
Source:http://www.medscape.com/viewarticle/709108_2
Abstract
Mortality rates were similar in patients who received single doses of etomidate or ketamine.
Introduction
Despite etomidate's hemodynamic benefits, some clinicians have challenged its use for rapid sequence intubation (RSI) in critically ill patients, citing concerns about adrenal insufficiency (JW Emerg Med [online] Feb 1 2008). In a prospective trial, researchers compared outcomes in 469 adult patients who were randomized to receive a single intravenous bolus of etomidate (0.3 mg/kg) or ketamine (2.0 mg/kg) for induction during RSI at 65 intensive care units (ICUs) and 12 emergency departments or prehospital systems in France. All patients received IV succinylcholine (1 mg/kg) immediately after the trial medication and continuous sedation with midazolam (0.1 mg/kg/hour) combined with fentanyl or sufentanil after tube placement was confirmed.
Final diagnoses were categorized as trauma (22%), sepsis (16%), or other (including stroke, overdose, cardiogenic shock, and acute respiratory failure; 62%). Adrenal insufficiency occurred in significantly more etomidate recipients than ketamine recipients (86% vs. 48%; odds ratio, 6.7). However, no significant differences were noted between groups in maximum sequential organ failure assessment (SOFA) scores during the first 3 days in the ICU (the primary outcome), intubation conditions, various measures of catecholamine use, or 28-day mortality. No drug-related adverse outcomes were reported with either agent. The authors conclude that "ketamine is a safe and valuable alternative to etomidate for intubation in critically ill patients, particularly in septic patients." Editorialists suggest that successful intubation depends on a solid knowledge of pharmacology but do not recommend one agent over the other.
Comment
This elegant and ambitious study demonstrated measurable adrenal suppression but no evidence of adverse outcome related to a single bolus of etomidate for RSI in patients with various types of shock. Adrenal axis suppression is common in critically ill patients; in fact, about half the patients who received ketamine had adrenal insufficiency in this study. The authors note that only 16% of study patients had septic shock, and they call for a larger randomized study that includes more patients with sepsis. Clinicians should choose induction drugs based on individual patient parameters and personal familiarity and not be dissuaded from using either etomidate or ketamine based on concerns that are not supported by evidence.
Friday, November 27, 2009
Thursday, November 26, 2009
Rocuronium vs. Succinylcholine in the Emergency Department
Sumber:http://www.medscape.com/viewarticle/710599
Background: Two methods of paralysis are available for rapid sequence intubation (RSI) in the emergency department (ED): depolarizing agents such as succinylcholine, and non-depolarizing drugs such as rocuronium. Rocuronium is a useful alternative when succinylcholine is contraindicated. Contraindications to succinylcholine include allergy, history of malignant hyperthermia, denervation syndromes, and patients who are 24-48 h post burn or crush injury. Non-depolarizing drugs have the advantage of causing less pain due to post-paralysis myalgias. Clinical Question: Can rocuronium replace succinylcholine as the paralytic of choice for RSI in the ED? Evidence Review: Four relevant studies were selected from an evidence search and a structured review performed. Results: For the outcomes of clinically acceptable intubation conditions and time to onset, the two agents were not statistically significantly different. Succinylcholine seems to produce conditions that have higher satisfaction scores. Conclusion: Succinylcholine remains the drug of choice for ED RSI unless there is a contraindication to its usage.
Posted: 11/06/2009; J Emerg Med. 2009;37(2):183-188. © 2009 Elsevier Science, Inc.
Subscribe to:
Posts (Atom)